Psoriasis with atherosclerosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. age >= 18 years; 2. Presence of atherosclerotic plaques confirmed by imaging examinations and indication for plaque endarterectomy; 3. Willingness to comply with study procedures and participate throughout the entire study process; 4. Provision of a signed and dated informed consent form. 5. Psoriasis patients receiving biologic therapy group: patients with a clinical diagnosis of psoriasis who are currently receiving or have regularly received biologic therapy within the past 3 months (e.g., TNF-a inhibitors, IL-17/IL-23 inhibitors, etc.). 6. Psoriasis patients without biologic therapy group: patients with a clinical diagnosis of psoriasis who have never received biologic therapy; treatment with conventional systemic therapies or topical therapies is permitted. 7. Participants in the non-psoriasis control group are required to have no prior history of psoriasis and no exposure to psoriasis-related systemic treatments.
Exclusion criteria
Exclusion criteria: 1. History or presence of malignancy, autoimmune diseases, or other inflammatory disorders; 2. Presence of acute or chronic active infections; 3. Pregnant or breastfeeding women; 4. Severe organ dysfunction; 5. Individuals unable to understand the study procedures or provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution and functional status of immune cell subsets; | — |
Secondary
| Measure | Time frame |
|---|---|
| laboratory test results;Imaging assessment parameters;Demographic and clinical characteristics; | — |
Countries
China
Contacts
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine